It is estimated that 8 million Americans live with psoriasis (PsO), a chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful. The most common form of psoriasis is plaque psoriasis. Nearly one-quarter of all people with plaque PsO have cases that are considered moderate-to-severe.
Living with plaque PsO can be a challenge and impact life beyond a person's physical health, including emotional health, relationships, and handling the stressors of life. Psoriasis on highly visible areas of the body or sensitive skin, such as the scalp, hands, feet, and genitals, can have an increased negative impact on quality of life. The average patient experience is to cycle through approximately three topicals or conventional agents for ~3 years, but many report cycling through three, four or even five.[i] Recently, the International Psoriasis Council updated its guidelines to address just this, now suggesting that people living with psoriasis should consider systemic treatment after two rounds of topicals.
The impact of PsO was something that Maddox experienced firsthand. Doctors diagnosed him with moderate-to-severe plaque psoriasis at age 12, right before his teenage years. Post puberty and into his college years, he often had scaly plaques covering his body, which impacted him emotionally. He often hid his condition with long sleeves and pants even in the summer heat. After years of trying to manage his symptoms cycling through various topical treatment options, never with much luck, his doctor enrolled him in the ICONIC-ADVANCE clinical trial for ICOTYDE™ (icotrokinra).
For many with moderate-to-severe disease, targeted systemic treatments are key. The FDA recently approved ICOTYDE, a once-daily pill for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age and older who weigh at least 40 kg who are candidates for systemic therapy or phototherapy. It is a completely new option for first-line systemic treatment of plaque psoriasis.
In this interview, Dr. Ted Lain (board-certified dermatologist and Executive Director of the Austin Institute for Clinical Research in Austin, Texas)discusses how psoriasis works, why many patients remain undertreated, and what makes this new treatment approach different. Joining him ise Maddox, who is living with psoriasis and can share firsthand how the disease affects daily life, both physically and emotionally, and discuss his experience with the latest treatment.
Interview courtesy: Johnson & Johnson
INDICATION
WHAT IS ICOTYDE™ (icotrokinra)?
ICOTYDETM 200 mg is a prescription medicine used to treat moderate to severe plaque psoriasis in adults and children 12 years of age and older who weigh at least 88 pounds (40 kg), who may benefit from taking injections or medicines by mouth (systemic therapy) or treatment using ultraviolet or UV light (phototherapy).
IMPORTANT SAFETY INFORMATION
What is the most important information I should know about ICOTYDE?
ICOTYDE may cause serious side effects, including:
- Infections. Medicines that interact with the immune system, such as ICOTYDE, may lower your ability to fight infections and may increase your risk of infections. Your healthcare provider may check you for infections and tuberculosis (TB) before starting treatment and may treat you for TB before you begin treatment with ICOTYDE if you have a history of TB or have active TB. Your healthcare provider should watch you closely for signs and symptoms of TB during and after treatment with ICOTYDE.
Tell your healthcare provider right away if you have any infection or have symptoms of an infection, including:
|
|
Before taking ICOTYDE, tell your healthcare provider about all of your medical conditions, including if you:
- have an infection that does not go away or that keeps coming back.
- have tuberculosis (TB) or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). Avoid receiving live vaccines during treatment with ICOTYDE.
- have kidney problems.
- are pregnant or plan to become pregnant. It is not known if ICOTYDE can harm your unborn baby.
Pregnancy Safety Study. There is a pregnancy safety study for women who take ICOTYDE during pregnancy. The purpose of this study is to collect information about the health of you and your baby. If you are pregnant or become pregnant during treatment with ICOTYDE, you can report your pregnancy by calling 1-800-525-7763 or visiting ICOTYDE.com.
- are breastfeeding or plan to breastfeed. It is not known if ICOTYDE passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby during treatment with ICOTYDE.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
What are the possible side effects of ICOTYDE?
ICOTYDE may cause serious side effects. See “What is the most important information I should know about ICOTYDE?”
The most common side effects of ICOTYDE include:
|
|
These are not all the possible side effects of ICOTYDE. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit fda.gov/medwatch, or call 1-800-FDA-1088.
How should I take ICOTYDE?
- Take ICOTYDE exactly as your healthcare provider tells you to take it.
- Take ICOTYDE 1 time a day when you wake up on an empty stomach with water. Wait at least 30 minutes after taking ICOTYDE before eating food.
- If you have difficulty swallowing tablets, ICOTYDE can be dispersed in water. For more information, please read the Medication Guide.
- If you miss a dose of ICOTYDE, take the dose as soon as you remember and go back to your regular schedule the next day.


.jpg)
.jpg)